Sunshine Biopharma prices USD 6 million public offering at USD 0.5 per unit
Share
Listen to the news
Sunshine Biopharma prices USD 6 million public offering at USD 0.5 per unit
  • Sunshine Biopharma priced a $6 million public offering on a best-efforts basis.
  • The deal comprises 12,000,000 common units or pre-funded units priced at $0.5 per common unit, each paired with two Series C warrants.
  • The Series C warrants carry an initial exercise price of $0.5, are exercisable immediately, and expire five years from issuance.
  • Closing is expected on or about May 19, 2026, with proceeds earmarked for general corporate purposes and working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605181215ACCESSWRNAPR_____1167768) on May 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending